NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

COVID-19 All NICE products on COVID-19. Includes any guidance and advice. Published products on this topic (13) ...

How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund ...

Thousands could benefit from first immunotherapy for severe birch tree pollen allergy We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to ...

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair ...

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma Technology appraisal guidance TA10 Published: 23 August 2000 ...

About our guidance We use the best available evidence to develop guidance to improve health and social care. Our guidance takes many forms: NICE guidelines (clinical, social care, public health, ...

Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. Commercial ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling ...